Kamada (KMDA) Price & Analysis

Compare

14 Followers

KMDA Stock Chart & Stats

2300.00

1.39(5.72%)

At close: Jan 08 4:00 PM EST

2300.00

1.39(5.72%)

Day’s Range― - ―

52-Week Range1,956.00 - 2,960.32

Previous CloseN/A

Volume698.59K

Average Volume (3M)107.22K

Market Cap

1.38B

Enterprise Value1.13B

Total Cash (Recent Filing)72.00M

Total Debt (Recent Filing)11.47M

Price to Earnings (P/E)18.2

Beta0.72

Next Earnings

Mar 18, 2026

EPS Estimate

25.25

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)29.78

Shares Outstanding57,681,590

10 Day Avg. Volume93,988

30 Day Avg. Volume107,216

Financial Highlights & Ratios

PEG Ratio0.31

Price to Book (P/B)1.28

Price to Sales (P/S)2.07

P/FCF Ratio9.03

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

4,169.17

Price Target Upside81.27% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)116.81

Revenue Forecast (FY)58.04B

Bulls Say, Bears Say

Bulls Say

Business RefocusThe decision to discontinue the Phase 3 Inhaled AAT clinical trial helps refocus the company on its core products and eliminates a distraction that was unlikely to be fruitful.

Financial PositionWith the discontinuation of the InnovAATe trial, Kamada is in a better financial position to pursue new commercial stage business.

Revenue GrowthKamada reported 3Q25 total revenues of $47.0M, representing a 13% increase from 3Q24.

Bears Say

Trial Enrollment ChallengesTrial enrollment for the inhaled AAT program continues to be an overhang, with enrollment only at 60% to 65% of the reduced sample size.

Kamada News

Midday Fly By: Micron reports Q1 beat, Trump Media to merge with TAE

The major averages were broadly higher near noon as investors react to the release of the delayed November...

5d ago

ACN

Kamada reiterates FY25 revenue guidance $178M-$182M

“This award extension, together with continued supply of KAMRAB, our anti-Rabies Immunoglobulin product used in Canada, and GLASSIA,...

5d ago

KMDA

Kamada announces $10M-$14M extension of Canadian supply tender

Kamada (KMDA) has been awarded an extension of an existing tender from the Canadian Blood Services for the...

5d ago

KMDA

Kamada price target raised to $13 from $11 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Kamada (KMDA) to $13 from $11 and keeps a Buy...

14d ago

KMDA

Midday Fly By: IBM to buy Confluent, Paramount goes hostile for Warner Bros.

The major averages were lower near noon as markets brace for the Federal Reserve’s rate-decision later this week....

15d ago

Kamada discontinues Phase 3 inhaled AAT clinical trial

Kamada (KMDA) announced that the independent Data and Safety Monitoring Board advised the Company that, based on a...

15d ago

KMDA

Kamada reiterates FY25 revenue guidance $178M-$182M

“While we are disappointed that the trial did not pass this milestone and is being discontinued, we are...

15d ago

KMDA

Kamada Wins $10–$14 Million Extension of Canadian Plasma-Product Tender

Kamada ( ($IL:KMDA) ) has shared an announcement. On December 18, 2025, Kamada Ltd. announced it has secured...

5d ago

KMDA

Kamada Ltd. Shareholders Approve Key Resolutions at Annual Meeting

The latest announcement is out from Kamada ( ($IL:KMDA) ). On December 10, 2025, Kamada Ltd. held its...

13d ago

KMDA

Kamada Discontinues Phase 3 Inhaled AAT Trial, Projects Growth in 2026

The latest update is out from Kamada ( ($IL:KMDA) ). On December 8, 2025, Kamada Ltd. announced the...

15d ago

KMDA

Kamada’s Growth Potential and Strategic Development Justify Buy Rating

Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Kamada, retaining the price target of $11.00....

1M ago

KMDA

Kamada Ltd. Reports Strong Financial Growth in 2025

Kamada Ltd ( ($KMDA) ) has released its Q3 earnings. Here is a breakdown of the information Kamada...

1M ago

KMDA

Kamada Ltd. Reports Strong Growth Amid Challenges

Kamada Ltd (($IL:KMDA)) has held its Q3 earnings call. Read on for the main highlights of the call....

1M ago

KMDA

Kamada Ltd. Reports Strong Q3 2025 Financial Results with 30% Profit Growth

An announcement from Kamada ( ($IL:KMDA) ) is now available. Kamada Ltd. reported strong financial results for the...

1M ago

KMDA

KMDA FAQ

What was Kamada’s price range in the past 12 months?

Kamada lowest stock price was 1956.00 and its highest was 2960.32 in the past 12 months.

What is Kamada’s market cap?

Kamada’s market cap is 1.38B.

When is Kamada’s upcoming earnings report date?

Kamada’s upcoming earnings report date is Mar 18, 2026 which is in 85 days.

How were Kamada’s earnings last quarter?

Kamada released its earnings results on Nov 10, 2025. The company reported 29.783 earnings per share for the quarter, the consensus estimate of 29.783 by 0.

Is Kamada overvalued?

According to Wall Street analysts Kamada’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kamada pay dividends?

Kamada pays a Notavailable dividend of 71.008 which represents an annual dividend yield of N/A. See more information on Kamada dividends here

What is Kamada’s EPS estimate?

Kamada’s EPS estimate is 25.25.

How many shares outstanding does Kamada have?

Kamada has 57,681,590 shares outstanding.

What happened to Kamada’s price movement after its last earnings report?

Kamada reported an EPS of 29.783 in its last earnings report, expectations of 29.783. Following the earnings report the stock price went up 5.145%.

Which hedge fund is a major shareholder of Kamada?

Currently, no hedge funds are holding shares in IL:KMDA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Kamada Stock Smart Score

Neutral

Fundamentals

Return on Equity

7.86%

Trailing 12-Months

Asset Growth

7.40%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Kamada

Kamada Ltd. is a biopharmaceutical company specializing in the development, production, and commercialization of innovative therapeutics. The company focuses on plasma-derived protein therapeutics, particularly for the treatment of rare diseases and respiratory conditions. Kamada's core products include immunoglobulins and other protein-based therapies that are essential for patients with specific medical needs, which are manufactured through advanced bioprocessing techniques.

Kamada (KMDA) Earnings & Revenues

Historic Earnings Reports

KMDA Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a positive outlook with strong revenue growth, increased EBITDA, and successful product launches. However, challenges remain with declining Glacia royalties, below-plan Cytogam sales, and slow clinical trial enrollment.View all IL:KMDA earnings summaries

KMDA Stock 12 Month Forecast

Average Price Target

4,169.17

▲(81.27% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1823":"1,823","4170":"4,170","2409.75":"2,409.8","2996.5":"2,996.5","3583.25":"3,583.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4169.165494,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">4.17K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4169.165494,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">4.17K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4169.165494,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">4.17K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1823,2409.75,2996.5,3583.25,4170],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2212,2362.551191846154,2513.1023836923077,2663.6535755384616,2814.2047673846155,2964.7559592307693,3115.307151076923,3265.8583429230766,3416.409534769231,3566.9607266153844,3717.5119184615387,3868.063110307692,4018.614302153846,{"y":4169.165494,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2212,2362.551191846154,2513.1023836923077,2663.6535755384616,2814.2047673846155,2964.7559592307693,3115.307151076923,3265.8583429230766,3416.409534769231,3566.9607266153844,3717.5119184615387,3868.063110307692,4018.614302153846,{"y":4169.165494,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2212,2362.551191846154,2513.1023836923077,2663.6535755384616,2814.2047673846155,2964.7559592307693,3115.307151076923,3265.8583429230766,3416.409534769231,3566.9607266153844,3717.5119184615387,3868.063110307692,4018.614302153846,{"y":4169.165494,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1824.8,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1997.85,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2107.707,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2182.566,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2409.086,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2484,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2371,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2363,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2622,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2547,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2407,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2282,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2212,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >